Last reviewed · How we verify
Isavuconazonium sulfate capsules
At a glance
| Generic name | Isavuconazonium sulfate capsules |
|---|---|
| Also known as | Cresemba |
| Sponsor | Astellas Pharma Global Development, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi (PHASE3)
- Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis (PHASE3)
- A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants (PHASE2)
- A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants (PHASE1)
- Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy (PHASE2, PHASE3)
- A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants (PHASE1)
- Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: